Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket [Seeking Alpha]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Seeking Alpha
Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarketSage Therapeutics (NASDAQ:SAGE) is up52% premarket on light volume in response to itsannouncement of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder (MDD), a Fast Track indication in the U.S.The 89-subject study met its primary endpoint of a statistically significant average reduction in HAM-D score from baseline to day 15 (p8:00 am ET to discuss the results.SAGE-217, a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system (CNS), plays a key role in regulating CNS function. The company intends to advance the program into Phase 3 development.See all stocks on the move »
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $34.00 to $19.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $25.00 to $17.00. They now have a "market perform" rating on the stock.MarketBeat
SAGE
Earnings
- 2/14/24 - Beat
SAGE
Sec Filings
- 4/19/24 - Form 8-K
- 4/17/24 - Form 8-K
- 3/27/24 - Form SC
- SAGE's page on the SEC website